Private Market View

Beichen Biotechnology

Shenzhen, China · Founded 2021 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
Last round

Key facts

  • Notable investors include TusStar Incubator, Fan Zhuo Capital, Shenzhen Lihe Science and Technology Innovation.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 3 names
  • ·Watchlist + deal alerts for Beichen Biotechnology
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Beichen Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Beichen Biotechnology

Provider of biotechnology research services designed for diagnostic and analytical purposes. The company offers detection systems, biochemical assay development, laboratory instrumentation, reagent preparation, and supporting technical services, enabling healthcare, pharmaceutical, and research markets to strengthen diagnostic accuracy, expand application in clinical and laboratory environments, improve reliability of testing workflows, enhance scalability of analytical processes, and support localized innovation capacity through structured research, production, and service integration.

Sector
Healthcare
HQ
Shenzhen, China
Founded
2021
Ownership
Privately Held (backing)
PA Mark — not yet priced

Beichen Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Beichen Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Beichen Biotechnology in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.